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Muawyah D. Al-Bdour, MDAbstractPurpose: To study the prevalence, manifestations and severity of ocular involvement of Behçet’s disease in Jordanian patients.
Methods: The study population consisted of 43 patients diagnosed to have Behçet’s disease through Rheumatologist’s examin-
ations conducted at Jordan University Hospital between January 2002 and July 2009. The sample involved patients who displayed
ocular manifestations. This included 18 patients; 12 males and 6 females with a mean age of 35 years (SD = 17.26). Ophthalmo-
logical examinations and retrospective analysis of medical files were carried on.
Results: Ocular manifestations were seen in 41.9% of patients. The most common manifestation for Behçet’s disease was vitritis
with a prevalence of 55.6%, followed by anterior uveitis and retinal vasculitis (50% for each). On the other hand, the most frequent
complications involved were cataract, cystoid macular edema (CMO), posterior synechiae and glaucoma with a prevalence of
(44.4%), (33.3%), (11.1%) and (5.6%), respectively.
Conclusion: The prevalence and severity of ocular lesions in Behçet’s disease is relatively low in Jordanian patients. This result indi-
cates that early diagnoses and intervention might delay or even prevent vision loss for those patients.
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Behçet’s disease is a chronic, recurrent, multisystem, auto-
immune disorder of unknown etiology. This disease is charac-
terized by the triad of oral ulcers, genital ulcers, and ocular
lesions.
In 1937 Dr. Hulusi Behçet, a Turkish Dermatology profes-
sor described the triple symptom complex of recurrent oral
ulcers, genital ulcers and iritis as a distinct entity. Professor
Behçet did not associate the disease with any known etiol-
ogy, but blamed unknown virus.1
Several sets of diagnostic criteria had been in use until
1990 when the International Study Group (ISG) for Behcet’s
disease proposed a new set of criteria.2 The ISG requires
recurrent oral ulcers as a mandatory criterion plus two of fourcriteria, including recurrent genital ulcers, skin lesions, uveitis
and a positive pathergy test.3
Behcet’s disease has a worldwide distribution, being more
common among populations with a higher prevalence of HLA
B5 and its split, HLA B 51, in the Mediterranean basin, the
Middle East and Far East.4
The etiopathogenesis of the disease is still unknown. It is
thought that in genetically susceptible individuals there is
an enhanced nonspecific inflammatory response, evident as
a skin pathergy reaction. Environmental triggers most proba-
bly microbial antigens, induce an antigen-driven specific
inflammatory response superimposed on this hyperreactivity.
This leads to endothelial dysfunction and occlusive
vasculopathy that may affect all types and sizes of vessels in
the body.5e:
al.com
53399.
Table 1. The prevalence of Male versus female patients distributed on
study variables.
Ocular manifestation % (n)
Males Females
Extraocular muscle paralysis 0 100% (2)
Anterior uvitis 77.8%
(7)
22.2%
(2)
Vitritis 70% (7) 30% (3)
Retinal vasculities (vascular sheathing) 44.4%
(4)
55.6%
(5)
Vascular occlusion 66.7%
(2)
33.3%
(1)
Multifocal retinitis 100% (2) 0
Macular edema especially cystoids type
(CMO)
66.7%
(4)
33.3%
(2)
Epiretinal membrane (ERM) 66.7%
(4)
33.3%
(2)
Retinal atrophy 0 100% (1)
Papillitis 0 100% (1)
Optic atrophy 50% (1) 50% (1)
Papildema 50% (1) 50% (1)
Neovascularization elsewhere (NVE) 100% (1) 0
Table 2. Distribution of patients on study variables and ocular
manifestations.
Variable No
(n = 18)
% 95% CI P
value
Sex 1.09–1.57 .000
Male 12 66.7
Female 6 33.3
Age group (Year) 1.52–2.81 .000
19–29 6 33.3
30–39 8 44.4
40–49 1 5.6
50–59 1 5.6
60 & More 2 11.1
Duration (Year) 1.27–.262 .000
1–5 10 55.6
6–10 5 27.8
16–20 1 5.6
+20 2 11.1
Side 1.57–1.99 .000
Unilateral 5 27.8
Bilateral 13 72.2
Visual acuity (Snellen
chart)
.3746–
.7710
.000
1–0.8 9 50
0.7–0.5 2 11.1
0.4–0.2 4 22.2
0.1 1 5.6
CF to PL 2 11.1
Ocular lesions
Uveitis 9 50 .24 to .76 .001
Vitritis 10 55.6 .30 to .81 .000
CRVO 1 5.6 .06 to .17 .331
BRVO 1 5.6 .06 to .17 .331
Neovascularization 1 5.6 .06 to .17 .331
Retinal vasculitis 9 50 .24 to .76 .001
Retinal atrophy 1 5.6 .06 to .17 .331
Cranial nerve palsy 2 11.1 .05 to .27 .163
Optic nerve atrophy 2 11.1 .05 to
27
.163
Papillitis 1 5.6 .06 to .17 .331
Papileodema 1 5.6 .06 to .17 .331
Cystoids macular edema 6 33.3 .09 to .57 .010
Macular hole 1 5.6 .06 to .17 .331
Cataract 8 44.4 .19 to .70 .002
Glaucoma 1 5.6 .06 to .17 .331
Posterior syneachea 2 11.1 .05 to .27 .163
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severity in Jordanian patients with Behçet’s disease.
Methods
Participants
The Ethics board at Jordan University Hospital approved a
retrospective chart review for 43 patients diagnosed with
Behçet’s disease. Those patients were diagnosed by the
Rheumatology Department and then referred to the Oph-
thalmology Department in the period between January
2002 and July 2009. Male cases accounted for the majority
with 29 patients representing (67.4%) of Behcet’s disease
population at Jordan University Hospital. Meanwhile, the
number of female patients reached 14 with a percentage of
(32.6%). Patients aged between 1 and 72 years with a mean
age of 36.88 (SD = 13.85). A review of medical profiles re-
ported 10.79 years (SD = 9.11) as a mean duration of the
disease.
Materials
Comprehensive ophthalmological evaluations were con-
ducted including assessment of visual acuity, external ocular
examination, slit lamp biomicroscopy and a detailed fundus
examination. The intraocular pressure (IOP) was measured
using an applanation tonometer.
Results
According to Rheumatologist diagnoses at Jordan Univer-
sity Hospital; a total of 43 patients were identified with Be-
hçet’s disease between January 2002 and July 2009. This
included 29 males and 14 females. Patients’ mean age was
36.88 years (SD = 13.85). The mean duration of the disease
was 10.79 years (SD = 9.11).
All patients who displayed ocular manifestations (18) were
included in this study. There were 12 males (66.7%) and 6 fe-
males (33.3%) with a mean age of 35 years (SD = 17.26). The
mean duration of the disease was 9.22 years (SD = 9.95).
Statistical analysis was performed using SPSS version 17.
Descriptive statistics were presented to describe the distribu-
tion of the sample on study variables (Table 1).
Results displayed in Table 2, show that none of the
patients manifested signs of recurrent conjunctivitis, conjunc-
tival ulcers, episcleritis, scleritis, filamentary keratitis, mar-
ginal sterile corneal ulcers, retinal exudation, exudative
retinal detachment, vitreous hemorrhage, tractional retinal
detachment, neovascular glaucoma or phthisis bulbi.
Results also suggest that the most common ocular mani-
festations are vitritis (55.6%), anterior uveitis (50%), and reti-
nal vasculitis (50%). Although higher prevalence was seen
among male cases in the first two manifestations (70%) and
(77.8%) respectively, nevertheless, lower prevalence for male
patients was reported in the third (44.4%).
In addition, findings illustrate an equal prevalence for cys-
toid macular edema (CMO) and epiretinal membrane (ERM)
(33.3%). More males than females were affected 4:2 in both.
Moreover, our results report a low prevalence for retinal
vascular occlusion (16.7%). Two males (66.7%) and one fe-
male (33.3%) were involved in this manifestation.
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manifested optic atrophy and papilloedema. While two fe-
male cases (100%) manifested extraocular muscle paralysis
and two males (100%) displayed signs of multifocal retinitis
these four manifestations rated a prevalence of two (11.1%)
each.
Finally, a single case of retinal atrophy (Fig. 1), papillitis
and NVEs (5.6%) was reported. A female patient with the first
two manifestations versus male patient with the last (NVEs).
Additionally, results also revealed evidence of complica-
tions. Cataract was the most frequent complication present
in 8 (44.4%) patients, followed by cystoid macular edema in
6 (33.3%) patients, posterior synechiae in 2 (11.1%) patients
and glaucoma in 1 (5.6%) patient.Discussion
Behçet’s disease is a systemic vasculitis involving many
organ systems and leading to a wide spectrum of
manifestations.6
Research in the medical field has proven that the eye is the
most commonly involved vital organ in Behçet’s disease.7,8
This paper aims to address the prevalence and ocular
manifestations involved in Behçet’s disease in a Jordanian
sample.
Studies conducted in Iran, Japan, China, Korea and Germany
(referred to as the five nation’s studies) reported the following
percentages of ocular manifestations: (55%), (69%), (35%),Figure 1. (a) Left mauclar OCt image shows significant reduction in retinal thi
patient with longstanding intraocular inflammation secondary to Behcet’s dis(51%) and (55%), respectively.9 A high prevalence of eye
involvement has also been reported in Arab countries such as
Morocco (67%)10 and Jordan (60%).
In the current study, however, the prevalence was 41.9%
which indicates a lower value than what was previously re-
ported in Jordan (60%).11
The male (with Behcet’s disease) to female ratio in our
study was 2:1. Different ratios comparing males to females
were reported in the five nation’s studies (1.19: 1, 0.98:1,
1.34:1, 0.63:1 and 1.40:1), respectively.9
Although the international study group of Behçet’s Dis-
ease has emphasized that the presence of recurrent oral ulcer
is the primary consideration in the diagnosis process.12 Oth-
ers argue that uveitis is the initial manifestation of the disease
in 10–20% of patients.13,14 Uveitis is classically defined as a
bilateral nongranulomatous panuveitis and retinal vasculitis.
However, uveitis may remain unilateral for many years in
some patients.15 In the current study we found that all af-
fected females and 75% of affected males had bilateral uve-
itis. Moreover, none of patients were diagnosed with uveitis
as a primary manifestation of Behçet’s disease.
Panuveitis and retinal vasculitis (Fig. 2) were the most fre-
quently reported eye lesions.15–18 Diffuse vitritis is a constant
feature of the posterior segment involvement, and spontane-
ous resolution is an important diagnostic feature.14 In our
study we reported vitritis in 55.6%, anterior uveitis in 50%,
and retinal vasculitis in 50%. Periphlebitis, a hallmark of Be-
hçet’s vasculitis may be both leaky and occlusive, retinal arte-
rioles and capillaries are also involved, Occlusion of retinalckness (160 l) as compared with OCT image (b) of the right eye (254 l) in
ease.
Figure 2. (A) Colored fundus photograph showing grade 1 vitritis (clear disk and vessels but retinal fiber layer obscured) with retinal vasculitis involving
superior temporal branch of retinal vein; (B) shows avascular peripheral retina with perivascular leakage 2ry to peripheral retinal vasculitis in patient with
behcet disease.
Figure 3. OCT of the left eye (a) shows cystoid macular edema involving the outer plexiform and inner nuclear layers of the sensory retina with small
sensory retinal detachment 2ry to viritis. FFA of the same eye (b) shows typical pattaloid appearance of cystoid macular edema with disk hyperfloresence
due to associated papillitis.
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to the tiny small branches.13 In this study we reported retinal
vein occlusion in 16.7% of patients.
Neovascularization of the disc (NVD) or elsewhere (NVE)
may develop as a complication of retinal vascular occlusion
or retinal ischemia induced by uncontrolled intraocular
inflammation. It was proven that retinal ischemia is responsi-
ble for 13% of eyes with NVD associated with Behçet’s uve-
itis.19 In this study only one patient (5.6%) had NVEs.
Optic neuropathy is a rare ocular involvement in Behçet’s
disease,20 it can be related to an inflammatory neuropathy, a
stasis Papilloedema complicating a benign intracranial hyper-
tension or an ischemic neuropathy, a case of simultaneous
bilateral anterior ischemic optic neuropathy (AION) with Be-
hçet’s disease was reported in one study.21 In the current
study one patient had bilateral papillitis and right 6th nerve
palsy. The same finding was reported in a case of Behcet’s
disease with acute neuro papillitis and 6th nerve palsy.22
Posterior segment involvement is the most serious ocular
complication of Behçet’s disease, leading to blindness with
recurrent attacks.23 Macular edema is the most common
complication which can evolve into cystoid degeneration
and occasionally macular hole.24 The development of partial
or full-thickness macular hole, though rarely reported, may
cause serious vision loss.25 In the current study, macular ede-
ma was reported in (33.3%) and macular hole (5.6%) with sig-
nificant vision loss was also noticed.
As reported8,15,18 the most common complications of Be-
hçet’s uveitis are cataract, posterior synechiae, macular ede-
ma (Fig. 3), optic atrophy, and glaucoma. In the current study
beside macular edema 33.3%, cataract 44.4%% posterior
synechiae and optic atrophy 11.11% for each and glaucoma
5.6% were found.Despite modern treatment and intervention strategies,
the disease still carries a poor visual prognosis with one-quar-
ter of the patients being blind.26 The disease is more severe
and the risk of losing useful vision is higher in males than in
females.14 In a Turkish study, it was reported that the esti-
mated risk of losing useful vision after 10 years was 30% in
males and 17% in females.14 In contrast, study on Behçet’s
disease in Korea revealed that females have a higher fre-
quency of ocular lesions than males.27 In the current study,
though the prevalence of male was higher, a significant vision
loss was higher in females, where 3 out of 6 females had vi-
sual acuity of 0.1 and less. Meanwhile, 7 out of the 12 males
had visual acuity of 0.8 and higher.Conflict of interest
The authors declared that there is no conflict of interest.
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